日本語フィールド
著者：Koji Takeuchi, Rintaro Sogawa, Satoko Tsuruhashi, Chika Motooka, Sakiko Kimura, Chisato Shimanoe題名：Antihypertensive Drug Combinations Modify Cisplatin-induced Acute Kidney Injury発表情報：In Vivo 巻: 36 号: 3 ページ: 1391-1396キーワード：Cisplatin; acute kidney injury; antihypertensive drug概要：Background/aim: There is limited evidence about the nephrotoxicity of calcium channel blockers (CCBs) and renin-angiotensin system (RAS) inhibitors with concomitant cisplatin (CDDP). We investigated whether combinations of antihypertensive drugs are associated with CDDP-related acute kidney injury (AKI) using the Japanese Adverse Drug Event Report database.
Patients and methods: We analysed 544,864 reports in the database from 2004 to 2020. A reporting odds ratio (ROR) and confidence interval (CI) with adjustment for potential confounding factors was calculated for AKI for each drug and the combined use of the drugs and CDDP.
Results: CDDP, CCBs, and RAS inhibitors were all detected signals for AKI. The ROR in cases with concomitant use of CCBs, RAS inhibitors, and CDDP (adjusted ROR 7.28; 95% CI=5.56-9.54) was higher than that in cases with use of each drug.
Conclusion: AKI may require more attention when patients receiving CDDP take CCBs and RAS inhibitors together.抄録：英語フィールド
Author：Koji Takeuchi, Rintaro Sogawa, Satoko Tsuruhashi, Chika Motooka, Sakiko Kimura, Chisato ShimanoeTitle：Antihypertensive Drug Combinations Modify Cisplatin-induced Acute Kidney InjuryAnnouncement information:In Vivo Vol: 36 Issue: 3 Page: 1391-1396Keyword：Cisplatin; acute kidney injury; antihypertensive drugAn abstract：Background/aim: There is limited evidence about the nephrotoxicity of calcium channel blockers (CCBs) and renin-angiotensin system (RAS) inhibitors with concomitant cisplatin (CDDP). We investigated whether combinations of antihypertensive drugs are associated with CDDP-related acute kidney injury (AKI) using the Japanese Adverse Drug Event Report database.
Patients and methods: We analysed 544,864 reports in the database from 2004 to 2020. A reporting odds ratio (ROR) and confidence interval (CI) with adjustment for potential confounding factors was calculated for AKI for each drug and the combined use of the drugs and CDDP.
Results: CDDP, CCBs, and RAS inhibitors were all detected signals for AKI. The ROR in cases with concomitant use of CCBs, RAS inhibitors, and CDDP (adjusted ROR 7.28; 95% CI=5.56-9.54) was higher than that in cases with use of each drug.
Conclusion: AKI may require more attention when patients receiving CDDP take CCBs and RAS inhibitors together.